CLINICAL TRIALS PROFILE FOR CAYSTON

All Clinical Trials for CAYSTON

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01746095 ↗	Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients	Completed	Cystic Fibrosis Foundation	Phase 2	2013-03-01	The purpose of this study is to determine whether AeroVanc treatment is safe and effective in reducing the number of MRSA colony forming units in the lungs of cystic fibrosis patients.
NCT01746095 ↗	Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients	Completed	Cystic Fibrosis Foundation Therapeutics	Phase 2	2013-03-01	The purpose of this study is to determine whether AeroVanc treatment is safe and effective in reducing the number of MRSA colony forming units in the lungs of cystic fibrosis patients.
NCT01746095 ↗	Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients	Completed	Synteract, Inc.	Phase 2	2013-03-01	The purpose of this study is to determine whether AeroVanc treatment is safe and effective in reducing the number of MRSA colony forming units in the lungs of cystic fibrosis patients.
NCT01746095 ↗	Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients	Completed	Savara Inc.	Phase 2	2013-03-01	The purpose of this study is to determine whether AeroVanc treatment is safe and effective in reducing the number of MRSA colony forming units in the lungs of cystic fibrosis patients.
NCT02449031 ↗	Observational Study in Cystic Fibrosis Patients Using TOBI® Podhaler™ or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs	Active, not recruiting	Cystic Fibrosis Foundation		2015-05-05	This is a multicenter, prospective, two cohort, observational study over a 5-year period in Cystic Fibrosis (CF) patients with chronic Pseudomonas aeruginosa infection.The study will collect data over 1 year on respiratory function, antibacterial effectiveness, and clinical outcomes of treatment with inhaled antipseudomonal antibiotics and data over 5 years on microbiological and safety assessments.
NCT02449031 ↗	Observational Study in Cystic Fibrosis Patients Using TOBI® Podhaler™ or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs	Active, not recruiting	Cystic Fibrosis Foundation Therapeutics		2015-05-05	This is a multicenter, prospective, two cohort, observational study over a 5-year period in Cystic Fibrosis (CF) patients with chronic Pseudomonas aeruginosa infection.The study will collect data over 1 year on respiratory function, antibacterial effectiveness, and clinical outcomes of treatment with inhaled antipseudomonal antibiotics and data over 5 years on microbiological and safety assessments.
NCT02449031 ↗	Observational Study in Cystic Fibrosis Patients Using TOBI® Podhaler™ or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs	Active, not recruiting	Mylan Inc.		2015-05-05	This is a multicenter, prospective, two cohort, observational study over a 5-year period in Cystic Fibrosis (CF) patients with chronic Pseudomonas aeruginosa infection.The study will collect data over 1 year on respiratory function, antibacterial effectiveness, and clinical outcomes of treatment with inhaled antipseudomonal antibiotics and data over 5 years on microbiological and safety assessments.

Clinical Trial Conditions for CAYSTON

Condition Name

Condition Name for CAYSTON
Intervention	Trials
Cystic Fibrosis	3
Bronchiectasis Adult	1
Infection	1
Pseudomonas	1

Condition MeSH

Condition MeSH for CAYSTON
Intervention	Trials
Cystic Fibrosis	4
Fibrosis	4
Pseudomonas Infections	3
Bronchiectasis	1

Clinical Trial Locations for CAYSTON

Trials by Country

Trials by Country for CAYSTON
Location	Trials
United States	56
United Kingdom	2

Trials by US State

Trials by US State for CAYSTON
Location	Trials
California	3
Washington	2
Utah	2
Texas	2
Tennessee	2

Clinical Trial Progress for CAYSTON

Clinical Trial Phase

Clinical Trial Phase for CAYSTON
Clinical Trial Phase	Trials
Phase 4	2
Phase 2	3

Clinical Trial Status

Clinical Trial Status for CAYSTON
Clinical Trial Phase	Trials
Terminated	2
Active, not recruiting	2
Completed	2

Clinical Trial Sponsors for CAYSTON

Sponsor Name

Sponsor Name for CAYSTON
Sponsor	Trials
Gilead Sciences	2
Cystic Fibrosis Foundation	2
Cystic Fibrosis Foundation Therapeutics	2

Sponsor Type

Sponsor Type for CAYSTON
Sponsor	Trials
Other	11
Industry	6